Compare NEOG & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | AMLX |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1995 | 2021 |
| Metric | NEOG | AMLX |
|---|---|---|
| Price | $9.51 | $16.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.67 | ★ $21.56 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $894,661,000.00 | $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $466.25 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $4.53 | $4.41 |
| 52 Week High | $11.43 | $18.61 |
| Indicator | NEOG | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 48.78 |
| Support Level | $8.98 | $12.29 |
| Resistance Level | $10.12 | $17.22 |
| Average True Range (ATR) | 0.36 | 0.81 |
| MACD | 0.00 | -0.26 |
| Stochastic Oscillator | 56.25 | 19.91 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.